StockData
Cardiff Oncology, Inc. logo

Cardiff Oncology, Inc. (CRDF) stock

CRDFNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$0.85−0.04 (-4.46%)

Close on Nov 20, 2026Market cap $66.34MP/E –Yield –

Cardiff Oncology profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Cardiff Oncology's profit margin for the twelve months ending Jun 30, 2026 was -7884.1%. For fiscal 2025 it was -7732.0%, against -6651.7% the year before. The highest annual figure on record is -868.9% in fiscal 2011.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-7732.0%−1080.4
FY2024Dec 31, 2024-6651.7%+1840.3
FY2023Dec 31, 2023-8492.0%+1534.9
FY2022Dec 31, 2022-10026.9%−2146.4
FY2021Dec 31, 2021-7880.5%−2605.4
FY2020Dec 31, 2020-5275.1%+1434.6
FY2019Dec 31, 2019-6709.7%−2358.7
FY2018Dec 31, 2018-4351.1%+577.0
FY2017Dec 31, 2017-4928.1%+5359.7
FY2016Dec 31, 2016-10287.7%−1505.8
FY2015Dec 31, 2015-8782.0%−3669.0
FY2014Dec 31, 2014-5113.0%−557.1
FY2013Dec 31, 2013-4555.9%−1988.0
FY2012Dec 31, 2012-2567.9%−1699.0
FY2011Dec 31, 2011-868.9%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-8876.9%+2646.2
Q1 FY2026Mar 31, 2026-30109.8%−17785.0
Q4 FY2025Dec 31, 2025-2969.5%+4836.4
Q3 FY2025Sep 30, 2025-9381.7%−2196.8
Q2 FY2025Jun 30, 2025-11523.1%−4297.4
Q1 FY2025Mar 31, 2025-12324.8%−7441.4
Q4 FY2024Dec 31, 2024-7806.0%−1820.7
Q3 FY2024Sep 30, 2024-7184.8%−283.4
Q2 FY2024Jun 30, 2024-7225.8%+3098.3
Q1 FY2024Mar 31, 2024-4883.4%+8638.3
Q4 FY2023Dec 31, 2023-5985.3%+809.3
Q3 FY2023Sep 30, 2023-6901.4%+2314.7
Q2 FY2023Jun 30, 2023-10324.1%+1151.8
Q1 FY2023Mar 31, 2023-13521.7%+1333.7
Q4 FY2022Dec 31, 2022-6794.5%+304.7
Q3 FY2022Sep 30, 2022-9216.1%−1177.8
Q2 FY2022Jun 30, 2022-11475.8%−1539.1
Q1 FY2022Mar 31, 2022-14855.4%−7662.3
Q4 FY2021Dec 31, 2021-7099.2%−1555.6
Q3 FY2021Sep 30, 2021-8038.4%−4731.8
Q2 FY2021Jun 30, 2021-9936.8%−346.1
Q1 FY2021Mar 31, 2021-7193.1%−1179.8
Q4 FY2020Dec 31, 2020-5543.7%−961.0
Q3 FY2020Sep 30, 2020-3306.6%+4706.1
Q2 FY2020Jun 30, 2020-9590.7%+1166.8
Q1 FY2020Mar 31, 2020-6013.2%+282.6
Q4 FY2019Dec 31, 2019-4582.7%+747.6
Q3 FY2019Sep 30, 2019-8012.7%−3746.6
Q2 FY2019Jun 30, 2019-10757.5%−7406.5
Q1 FY2019Mar 31, 2019-6295.9%−1516.2
Q4 FY2018Dec 31, 2018-5330.4%−3941.5
Q3 FY2018Sep 30, 2018-4266.1%−786.0
Q2 FY2018Jun 30, 2018-3351.1%+4536.1
Q1 FY2018Mar 31, 2018-4779.7%+5741.9
Q4 FY2017Dec 31, 2017-1388.9%+11181.2
Q3 FY2017Sep 30, 2017-3480.1%+7970.8
Q2 FY2017Jun 30, 2017-7887.2%–
Q1 FY2017Mar 31, 2017-10521.6%–
Q4 FY2016Dec 31, 2016-12570.1%–
Q3 FY2016Sep 30, 2016-11450.9%–

More Cardiff Oncology figures

See a number that looks wrong?